Revvity saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 68 to 74.
IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks often have an RS Rating north of 80 as they launch their largest climbs. See if Revvity can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Revvity is trying to complete a flat base with a 128.15 entry. See if it can clear the breakout price in heavy volume.
Taking a look at top and bottom line numbers, the company has posted rising EPS growth over the last two quarters. Revenue gains have also risen over the same time frame.
Revvity earns the No. 12 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Bio-Rad Labs A are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
